FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979001489> ?p ?o ?g. }

• W1979001489 endingPage "532" @default.
• W1979001489 startingPage "525" @default.
• W1979001489 abstract "Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, is cured with conventional therapy in 70%. However, the 5-year survival for those who relapse is about 30%, and drops to about 15% for those with unfavorable histologies (alveolar/undifferentiated subtypes). We describe outcomes of 62 subjects receiving autologous blood/bone marrow (BM) transplants for RMS between 1989 and 2003, and reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR). Histologic subtype was confirmed by reviewing pathology reports. Treatment-related mortality (TRM), progression-free survival (PFS), and overall survival (OS) were evaluated. Overall, 73% of subjects were <20 years; 39% had cancer bulk >5 cm, 63% had metastasis at diagnosis, 55% had unfavorable histologies, 92% had cancer responsive to chemotherapy pretransplant, and 67% were in first remission. The 1-year TRM was 5% (95% confidence interval [CI], 1%-12%) and the 5-year PFS and OS were 29% (95% CI, 18%-41%) and 32% (95% CI, 21%-44%), respectively. There was only a 4% relapse rate after the first year. There were no differences in 5-year PFS or survival based on histological subtype, transplant in first remission versus relapse (36% versus 29%; P = .5), or transplantation for poor-risk histologies in first remission versus relapse (34% versus 33%; P = .9). Our data indicate that autotransplants for RMS disease are typically done in patients with disease responsive to chemotherapy pretransplant, with approximately one-third long-term survivors. Despite high-risk factors, we also found a low TRM, perhaps reflecting the migration from marrow to blood stem cells as the graft source. Even when performed after relapse for alveolar/undifferentiated histologies, long-term survivals were seen seemingly better than results with conventional therapies. Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, is cured with conventional therapy in 70%. However, the 5-year survival for those who relapse is about 30%, and drops to about 15% for those with unfavorable histologies (alveolar/undifferentiated subtypes). We describe outcomes of 62 subjects receiving autologous blood/bone marrow (BM) transplants for RMS between 1989 and 2003, and reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR). Histologic subtype was confirmed by reviewing pathology reports. Treatment-related mortality (TRM), progression-free survival (PFS), and overall survival (OS) were evaluated. Overall, 73% of subjects were <20 years; 39% had cancer bulk >5 cm, 63% had metastasis at diagnosis, 55% had unfavorable histologies, 92% had cancer responsive to chemotherapy pretransplant, and 67% were in first remission. The 1-year TRM was 5% (95% confidence interval [CI], 1%-12%) and the 5-year PFS and OS were 29% (95% CI, 18%-41%) and 32% (95% CI, 21%-44%), respectively. There was only a 4% relapse rate after the first year. There were no differences in 5-year PFS or survival based on histological subtype, transplant in first remission versus relapse (36% versus 29%; P = .5), or transplantation for poor-risk histologies in first remission versus relapse (34% versus 33%; P = .9). Our data indicate that autotransplants for RMS disease are typically done in patients with disease responsive to chemotherapy pretransplant, with approximately one-third long-term survivors. Despite high-risk factors, we also found a low TRM, perhaps reflecting the migration from marrow to blood stem cells as the graft source. Even when performed after relapse for alveolar/undifferentiated histologies, long-term survivals were seen seemingly better than results with conventional therapies." @default.
• W1979001489 created "2016-06-24" @default.
• W1979001489 creator A5000120418 @default.
• W1979001489 creator A5001697191 @default.
• W1979001489 creator A5013177563 @default.
• W1979001489 creator A5022161221 @default.
• W1979001489 creator A5031877880 @default.
• W1979001489 creator A5036295405 @default.
• W1979001489 creator A5039081532 @default.
• W1979001489 creator A5042915360 @default.
• W1979001489 creator A5054714265 @default.
• W1979001489 creator A5069907148 @default.
• W1979001489 creator A5076074380 @default.
• W1979001489 creator A5088486180 @default.
• W1979001489 date "2010-04-01" @default.
• W1979001489 modified "2023-10-06" @default.
• W1979001489 title "High-Dose Chemotherapy with Blood or Bone Marrow Transplants for Rhabdomyosarcoma" @default.
• W1979001489 cites W1895211074 @default.
• W1979001489 cites W1897723143 @default.
• W1979001489 cites W1905490737 @default.
• W1979001489 cites W1957951607 @default.
• W1979001489 cites W1973617793 @default.
• W1979001489 cites W1986157370 @default.
• W1979001489 cites W2024193398 @default.
• W1979001489 cites W2051071906 @default.
• W1979001489 cites W2069996052 @default.
• W1979001489 cites W2105895314 @default.
• W1979001489 cites W2143011127 @default.
• W1979001489 cites W2156822604 @default.
• W1979001489 cites W2160417212 @default.
• W1979001489 cites W2163193120 @default.
• W1979001489 cites W2166219545 @default.
• W1979001489 cites W2167270265 @default.
• W1979001489 cites W2551773592 @default.
• W1979001489 cites W4293241248 @default.
• W1979001489 doi "https://doi.org/10.1016/j.bbmt.2009.11.020" @default.
• W1979001489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2838953" @default.
• W1979001489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19961947" @default.
• W1979001489 hasPublicationYear "2010" @default.
• W1979001489 type Work @default.
• W1979001489 sameAs 1979001489 @default.
• W1979001489 citedByCount "10" @default.
• W1979001489 countsByYear W19790014892012 @default.
• W1979001489 countsByYear W19790014892013 @default.
• W1979001489 countsByYear W19790014892014 @default.
• W1979001489 countsByYear W19790014892015 @default.
• W1979001489 countsByYear W19790014892017 @default.
• W1979001489 crossrefType "journal-article" @default.
• W1979001489 hasAuthorship W1979001489A5000120418 @default.
• W1979001489 hasAuthorship W1979001489A5001697191 @default.
• W1979001489 hasAuthorship W1979001489A5013177563 @default.
• W1979001489 hasAuthorship W1979001489A5022161221 @default.
• W1979001489 hasAuthorship W1979001489A5031877880 @default.
• W1979001489 hasAuthorship W1979001489A5036295405 @default.
• W1979001489 hasAuthorship W1979001489A5039081532 @default.
• W1979001489 hasAuthorship W1979001489A5042915360 @default.
• W1979001489 hasAuthorship W1979001489A5054714265 @default.
• W1979001489 hasAuthorship W1979001489A5069907148 @default.
• W1979001489 hasAuthorship W1979001489A5076074380 @default.
• W1979001489 hasAuthorship W1979001489A5088486180 @default.
• W1979001489 hasBestOaLocation W19790014891 @default.
• W1979001489 hasConcept C126322002 @default.
• W1979001489 hasConcept C141071460 @default.
• W1979001489 hasConcept C142724271 @default.
• W1979001489 hasConcept C143998085 @default.
• W1979001489 hasConcept C2776694085 @default.
• W1979001489 hasConcept C2778256501 @default.
• W1979001489 hasConcept C2780007613 @default.
• W1979001489 hasConcept C2780844630 @default.
• W1979001489 hasConcept C2911091166 @default.
• W1979001489 hasConcept C44249647 @default.
• W1979001489 hasConcept C71924100 @default.
• W1979001489 hasConcept C90924648 @default.
• W1979001489 hasConceptScore W1979001489C126322002 @default.
• W1979001489 hasConceptScore W1979001489C141071460 @default.
• W1979001489 hasConceptScore W1979001489C142724271 @default.
• W1979001489 hasConceptScore W1979001489C143998085 @default.
• W1979001489 hasConceptScore W1979001489C2776694085 @default.
• W1979001489 hasConceptScore W1979001489C2778256501 @default.
• W1979001489 hasConceptScore W1979001489C2780007613 @default.
• W1979001489 hasConceptScore W1979001489C2780844630 @default.
• W1979001489 hasConceptScore W1979001489C2911091166 @default.
• W1979001489 hasConceptScore W1979001489C44249647 @default.
• W1979001489 hasConceptScore W1979001489C71924100 @default.
• W1979001489 hasConceptScore W1979001489C90924648 @default.
• W1979001489 hasFunder F4320306761 @default.
• W1979001489 hasFunder F4320307105 @default.
• W1979001489 hasFunder F4320307769 @default.
• W1979001489 hasFunder F4320307820 @default.
• W1979001489 hasFunder F4320308295 @default.
• W1979001489 hasFunder F4320308502 @default.
• W1979001489 hasFunder F4320308970 @default.
• W1979001489 hasFunder F4320308981 @default.
• W1979001489 hasFunder F4320308992 @default.
• W1979001489 hasFunder F4320309086 @default.
• W1979001489 hasFunder F4320309487 @default.
• W1979001489 hasFunder F4320309567 @default.
• W1979001489 hasFunder F4320309846 @default.

• next